balanc bid new blend pt
remain top pick eu
novo decis go public jan ablynx board flatli reject
two acquisit offer misguid view believ
bid under-valued asset see potenti counterbid given
compani cusp launch highli profit rare diseas drug
capla hike pt assum likelihood potenti
takeout vs stand-alone npv reiter buy top pick
eu biotech
see engag board deal ablynx board rebuf
cash bid novo nordisk novob dc
hold declin enter talk justifi view given higher base
case stand-alone npv deriv potenti takeout npv assum synergi novo
commercialis capla upsid phase ii success voba lupu
rsv year platform valu base conserv
mileston exist deal
capla potenti game-chang ablynx caplacizumab significantli curtail
costli plasma exchang riski procedur reduc risk exacerb protect
organ damag provid window physician resolv underli diseas
acquir ttp expect eu approv fda file shortli us
launch commercialis capla envisag highli profit ww peak sale
penetr assum wide adopt standard-of-car
npv probabl
pipelin signific option phase iib rsv result anticip
fully-own asset could crystallis signific valu ablynx
view phase ii result vobarilizumab system lupu erythematosu expect
trigger opt-in decis would also includ arthriti indic
focu partner programm includ two nanobodi drug i-o collabor
merck like enter clinic year
price base sum-of-the-part valuat blend
stand-alone takeout scenario includ probability-adjust npv caplacizumab
vobarilizumab plu net risk includ efficaci safeti regulatori
setback need execut out-licens allianc clinic trial failur delay
acquisit offer
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
optimist lead product caplacizumab rare
blood disord attp potenti transform ablynx
drug repres import contributor
numer pipelin programm
valu particular rsv infect partner
programm also gener licens incom
price per share per base sum-
of-the-part valuat blend
posit vobarilizumab data sle opt-in decis
could add potenti
increment new partner initi
phase ra indic
posit result phase iib trial rsv
infect infant could increas sum-of-the-part
valuat least
togeth potenti catalyst could boost
stand-alone npv deriv price around
believ potenti take-over offer could
includ synergi
caplacizumab potenti nanobodi platform valu
caplacizumab efficaci safeti concern regulatori
author could detriment valuat
remov least
phase ii vobarilizumab studi sle fail could
lower npv
efficaci safeti uncertainti phase iib trial
setback could reduc npv deriv price target
around end-septemb plu
gross proce us ipo suffici reach
caplacizumab
technolog deal expect licens revenu estim
prove conserv
us caplacizumab file attp around eu
approv
phase ii sle result vobarilizumab
phase iib result rsv infect infant
merck initi phase trial two i-o
nanobodi drug
futur potenti nanobodi platform licens deal
achiev mileston exist allianc
page
pleas see import disclosur inform page report
reiter buy price
impress posit phase hercul data lead product caplacizumab
rare blood disord attp underscor confid regulatori approv
continu believ caplacizumab potenti game-chang ablynx
remain larg underappreci investor despit highli
profit commerci opportun orphan diseas result
phase iib respir studi wholly-own inhal anti-rsv nanobodi alx-
could potenti trigger lucr partnership deal
remain cautiou commerci prospect vobarilizumab
given highli competit landscap biolog target addit
alreadi crowd market approv drug novel small molecul
clinic develop importantli numer early-stag allianc
nanobodi discoveri platform crystallis increment valu
view notabl broad immuno-oncolog collabor merck
mileston total reiter buy rate price
hike per share per assum
likelihood take-over boost probabl commerci success
caplacizumab
per share per price base sum-of-the-part valuat
assum blend stand-alone takeout scenario sum-of-the-part compris
probability-adjust npv caplacizumab vobarilizumab sle plu net
includ net mileston incom receiv partner
tabl ablynx sum-of-the-part valuat stand-alone basi
tabl sourc upsid potenti downsid risk
page
pleas see import disclosur inform page report
peakvalueadj valueeurindicationsal mn eurmn prob eurmn per sharecaplacizumab anti-vwf thrombot thrombocytopen purpura lupu anti-rsv rsv infect dilut fundingmin yr dilut sharedownsidep sharecaplacizumab approv attpema fda safeti and/or ranew partner initi new partner phase ii sleposit and/or reject rsv phase iib infect infantsposit and/or efficaci ablx bb
tabl deriv price target assum likelihood potenti takeout
suffici fund crystallis valu
ablynx rais gross proce us ipo octob togeth
cash septemb suggest current fund around believ
caplacizumab success launch around europ ablynx suffici
cash reach potenti break-even exclud possibl upsid increment
deal futur mileston given manag track record execut nanobodi
technolog deal expect licens revenu estim conserv
furthermor ablynx could out-licens anti-human serum albumin half-lif extens
technolog and/or product right
futur incom benefit belgian patent box legisl exempt ip
relat revenu taxat assum attract tax rate licens
incom caplacizumab manag may utilis transfer price take advantag
patent box even commerci right retain ablynx henc estim
blend tax rate profit
sale launch eu us assum
npv per share assum probabl success
news flow us file near futur possibl european approv
caplacizumab ablynx advanc project promis first therapeut
acquir thrombot thrombocytopen purpura attp potenti
transform treatment paradigm rare disord limit competit
market develop pipelin orphan drug design fda
ema plu fda track repres signific commerci opportun
view forecast global peak sale penetr attp patient treat
plasma exchang assum caplacizumab wide adopt standard-of-car
suggest npv probabl repres import
contributor sum-of-the-part key share price catalyst
europ ablynx pursu approv caplacizumab base titan phase ii result
phase hercul data ad dossier later date market
authoris applic submit ema februari potenti
approv chmp opinion around may-jun envisag us file soon
base posit hercul phase trial forecast caplacizumab launch around
europ us
caplacizumab met primari endpoint statist signific reduct
time platelet count respons rate ratio median vs day
patient receiv drug like achiev platelet count respons
page
pleas see import disclosur inform page report
potenti take-over valueeur/shareusd/sharenpv caplacizumab valuat npv take-over ablx bb
given time point versu placebo posit outcom support result
achiev phase ii titan trial confirm caplacizumab
prevent microvascular thrombosi
importantli first two key secondari endpoint also met demonstr
drug highli relev clinic benefit view like facilit discuss
payer price reimburs
composit endpoint reduc larg driven
substanti fewer recurr attp caplacizumab vs event
composit defin proport subject attp-rel death
recurr attp least one treatment-emerg major thromboembol
event studi drug treatment period note six patient
least one treatment-emerg major thromboembol event
arm potenti recurr attp subject placebo cohort could
recurr attp period day last dose
lower caplacizumab arm versu placebo vs subject note
six nine recurr caplacizumab cohort follow-up
period patient still wherea occur
treatment period placebo patient caplacizumab
attp recurr receiv drug maximum durat per protocol
believ demonstr caplacizumab patient protect
recurr enabl physician address underli diseas
time immunosuppress
case refractori attp caplacizumab cohort compar
three patient treat placebo miss statist signific
given lower number event refractori diseas defin absenc
platelet count doubl day standard treatment ldh uln
trend faster normalis three organ damag biomark
ldh cardiac troponin ctni serum creatinin
period day last dose
safeti profil caplacizumab broadli expect seriou treatment-
emerg advers event teae common placebo cohort given higher
recurr attp expect given mechan action bleeding-rel teae
frequent caplacizumab vs mild-moder
sever tesa drug mostli epistaxi nose bleed gingiv gum bleed
three death placebo cohort none caplacizumab group
treatment period one death drug arm follow-up due cerebr
ischaemia assess investig relat therapi note across
titan hercul trial treatment period five death placebo
versu none caplacizumab encourag sign albeit base event
importantli present detail data medic confer decemb
demonstr substanti reduct durat plasma exchang pex
hospitalis icu suggest meaning benefit payer
mean day plasma exchang vs placebo vs caplacizumab
respect volum plasma vs mean day
intens care vs day hospit vs
use recent intern ttp work group consensu definit
refractori attp five episod placebo vs none caplacizumab
contrast vs use pre-specifi definit
page
pleas see import disclosur inform page report
clinician discuss unanim suggest caplacizumab like
becom front line standard-of-car attp caveat rais
meet patient alreadi anticoagul given bleed risk
highli profit opportun could transform ablynx
forecast caplacizumab penetr estim us attp patient
episod nearli geographi ww peak sale assum
averag revenu per treatment respect commercialis
caplacizumab drug could repres highli profit opportun ablynx
addit indic investig
preclin data non-human primat trial caplacizumab reperfus injuri
embol stroke could present later year potenti demonstr drug
reduc reperfus injuri thrombectomi data support phase ii
trial may initi
page
pleas see import disclosur inform page report
eur million dec popul incid acquir ttp ttp patient hospitalis rate pex ttp patient event treat caplacizumab ttp patient averag revenu per patient per caplacizumab sale popul assum eu incid acquir ttp ttp patient hospitalis rate pex ttp patient event treat caplacizumab ttp patient averag revenu per patient per treatment caplacizumab sale caplacizumab sale caplacizumab sale sale growthn/a ablx bb
rsv therapi could market
sale assum use children age year
hospitalis rsv infect us europ
npv per share assum probabl success out-licens
deal phase iib result
news flow data phase iib respir efficaci studi hospitalis
infant could trigger partnership deal japanes phase ii studi
hospitalis infant begin addit phase iia trial rsv-
respiratori syncyti viru rsv caus sever morbid mortal respons
estim three million annual hospitalis children age five
lead viral caus infant death also recognis signific caus
respiratori ill among elderli high-risk adult despit substanti global
burden therapeut option limit select patient popul conduct
deep dive rsv develop landscap research suggest approv
rsv therapeut could potenti blockbust even limit hospitalis
infant age five year upsid use outpati set
inhal anti-rsv nanobodi phase ii develop treatment
hospitalis infant rsv infect innov trival nanobodi consist three
ident nanobodi link togeth peptid target protein trival
format result increas potenc whilst robust nanobodi enabl
maintain efficaci even nebulis offer less invas mode administr
infant elderli patient potenti faster onset action reduc chanc
phase i/ii demonstr anti-vir effect sign clinic efficaci
april ablynx report posit top-lin result phase i/iia studi
infant age month hospitalis rsv infect initi open label
lead-in phase five infant age month follow double-blind placebo-
control phase infant age month randomis either inhal
deliv via vibrat mesh devic placebo three consecut day
safe well toler meet primari endpoint treatment-
relat seriou advers event report follow-up treatment-emerg anti-drug
antibodi detect patient howev appar effect
pharmacokinet relationship seen advers event
tabl safeti toler phase i/iia studi
jefferi research ablynx present
note one subject discontinu subject discontinu
encouragingli show earli sign anti-vir effect measur rsv viral
replic viral load versu placebo show rapid immedi effect
infecti viral load measur plaqu assay six hour post-dos sustain
thereaft versu placebo reduct viral rna load measur qrt-pcr
also shown though lesser magnitud also superior placebo time
page
pleas see import disclosur inform page report
